SAN RAFAEL, Calif.--(BUSINESS WIRE)--Eastbourne Capital Management, L.L.C. (“Eastbourne”) today delivered a letter to the Amylin Pharmaceuticals, Inc. (“Amylin”) (NASDAQ: AMLN) Board of Directors. Eastbourne currently owns approximately 12.5% of Amylin’s outstanding shares. The full text of the letter is as follows:
